MAPT and Alzheimer disease: We believe that exploring the binding characteristicsof the tracers to PSP, CBD, and AD tau protofibrils can be valuableto establish and understand the structure–activity relationshipsbetween the known tracers and tau fibrils, as well as help to designnovel high-affinity and selectivity PET tracers targeting a specifictau fibril.